Malaria Vaccines Since 2000: Progress, Priorities, Products

Overview

Journal NPJ Vaccines

Date 2020 Jun 23

PMID 32566259

Citations 115

Authors

Patrick E Duffy

J Patrick Gorres

Affiliations

Soon will be listed here.

Abstract

Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic candidate RTS,S was favorably reviewed by the European Medicines Agency and subsequently introduced into national pilot implementation programs, marking the first human anti-parasite vaccine to pass regulatory scrutiny. Since the first trials published in 1997, RTS,S has been evaluated in a series of clinical trials culminating in Phase 3 testing, while testing of other pre-erythrocytic candidates (that target sporozoite- or liver-stage parasites), particularly whole sporozoite vaccines, has also increased. Interest in blood-stage candidates (that limit blood-stage parasite growth) subsided after disappointing human efficacy results, although new blood-stage targets and concepts may revive activity in this area. Over the past decade, testing of transmission-blocking vaccines (that kill mosquito/sexual-stage parasites) advanced to field trials and the first generation of placental malaria vaccines (that clear placenta-sequestering parasites) entered the clinic. Novel antigen discovery, human monoclonal antibodies, structural vaccinology, and improved platforms promise to expand on RTS,S and improve existing vaccine candidates.

Citing Articles

Computational Development of Transmission-Blocking Vaccine Candidates Based on Fused Antigens of Pre- and Post-fertilization Gametocytes Against .

Adeleke M Bioinform Biol Insights. 2025; 19:11779322241306215.

PMID: 40034580 PMC: 11873872. DOI: 10.1177/11779322241306215.

Evasive mechanisms of human VSG and PfEMP1 antigens with link to Vaccine scenario: a review.

Obi O, Obiezue R, Eze D, Adebote D J Parasit Dis. 2025; 49(1):13-28.

PMID: 39975623 PMC: 11833005. DOI: 10.1007/s12639-024-01740-9.

Knowledge and willingness towards malaria vaccines among caregivers in Dar es Salaam, Tanzania.

Mwingira F, Matiya D, Chacky F Malar J. 2025; 24(1):35.

PMID: 39910572 PMC: 11800513. DOI: 10.1186/s12936-024-05183-8.

Computational design, expression, and characterization of a multi-epitope, multi-stage vaccine candidate (PfCTMAG).

Chick J, Abongdia N, Shey R, Apinjoh T Heliyon. 2025; 11(2):e42014.

PMID: 39906795 PMC: 11791285. DOI: 10.1016/j.heliyon.2025.e42014.

Zinc from an Essential Element to an Antiparasitic Therapeutic Agent.

Navarro M, Daniel L, Colina-Vegas L, Visbal G ACS Omega. 2025; 10(3):2393-2414.

PMID: 39895759 PMC: 11780429. DOI: 10.1021/acsomega.4c07331.

References

Neafsey D, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A . Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med. 2015; 373(21):2025-2037. PMC: 4762279. DOI: 10.1056/NEJMoa1505819. View

Bongfen S, Ntsama P, Offner S, Smith T, Felger I, Tanner M . The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine. 2008; 27(2):328-35. DOI: 10.1016/j.vaccine.2008.09.097. View

Coelho C, Doritchamou J, Zaidi I, Duffy P . Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium. NPJ Vaccines. 2018; 2:34. PMC: 5709382. DOI: 10.1038/s41541-017-0035-3. View

Salanti A, Staalsoe T, Lavstsen T, Jensen A, Sowa M, Arnot D . Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol. 2003; 49(1):179-91. DOI: 10.1046/j.1365-2958.2003.03570.x. View

Carter R, Chen D . Malaria transmission blocked by immunisation with gametes of the malaria parasite. Nature. 1976; 263(5572):57-60. DOI: 10.1038/263057a0. View

Kaushal D, Carter R . Characterization of antigens on mosquito midgut stages of Plasmodium gallinaceum. II. Comparison of surface antigens of male and female gametes and zygotes. Mol Biochem Parasitol. 1984; 11:145-56. DOI: 10.1016/0166-6851(84)90061-6. View

Herrera R, Anderson C, Kumar K, Molina-Cruz A, Nguyen V, Burkhardt M . Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains. Infect Immun. 2015; 83(10):3771-80. PMC: 4567636. DOI: 10.1128/IAI.02676-14. View

Regules J, Cicatelli S, Bennett J, Paolino K, Twomey P, Moon J . Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. J Infect Dis. 2016; 214(5):762-71. DOI: 10.1093/infdis/jiw237. View

Kapulu M, Da D, Miura K, Li Y, Blagborough A, Churcher T . Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum. Sci Rep. 2015; 5:11193. PMC: 4463016. DOI: 10.1038/srep11193. View

10.

Battle K, Lucas T, Nguyen M, Howes R, Nandi A, Twohig K . Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet. 2019; 394(10195):332-343. PMC: 6675736. DOI: 10.1016/S0140-6736(19)31096-7. View

11.

Scally S, Murugan R, Bosch A, Triller G, Costa G, Mordmuller B . Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. J Exp Med. 2017; 215(1):63-75. PMC: 5748854. DOI: 10.1084/jem.20170869. View

12.

Pholcharee T, Oyen D, Torres J, Flores-Garcia Y, Martin G, Gonzalez-Paez G . Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite Protein. J Mol Biol. 2019; 432(4):1048-1063. PMC: 7057269. DOI: 10.1016/j.jmb.2019.12.029. View

13.

Siddiqui W . An effective immunization of experimental monkeys against a human malaria parasite, Plasmodium falciparum. Science. 1977; 197(4301):388-9. DOI: 10.1126/science.406671. View

14.

Agnandji S, Lell B, Fernandes J, Abossolo B, Methogo B, Lumeka Kabwende A . A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012; 367(24):2284-95. PMC: 10915853. DOI: 10.1056/NEJMoa1208394. View

15.

Rawlinson T, Barber N, Mohring F, Cho J, Kosaisavee V, Gerard S . Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody. Nat Microbiol. 2019; 4(9):1497-1507. PMC: 6711757. DOI: 10.1038/s41564-019-0462-1. View

16.

Oyen D, Torres J, Cottrell C, King C, Wilson I, Ward A . Cryo-EM structure of circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Sci Adv. 2018; 4(10):eaau8529. PMC: 6179375. DOI: 10.1126/sciadv.aau8529. View

17.

Kumar N . Target antigens of malaria transmission blocking immunity exist as a stable membrane bound complex. Parasite Immunol. 1987; 9(3):321-35. DOI: 10.1111/j.1365-3024.1987.tb00511.x. View

18.

Seder R, Chang L, Enama M, Zephir K, Sarwar U, Gordon I . Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013; 341(6152):1359-65. DOI: 10.1126/science.1241800. View

19.

Sirima S, Cousens S, Druilhe P . Protection against malaria by MSP3 candidate vaccine. N Engl J Med. 2011; 365(11):1062-4. DOI: 10.1056/NEJMc1100670. View

20.

Roestenberg M, McCall M, Hopman J, Wiersma J, Luty A, van Gemert G . Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009; 361(5):468-77. DOI: 10.1056/NEJMoa0805832. View